A masterful synchronization of history and cutting-edge science shines new light on humanity's darkest diagnosis.
In the wake of the Cancer Genome Atlas project's failure to provide a legible roadmap to a cure for cancer, science writer Travis Christofferson illuminates a promising blend of old and new perspectives on the disease. Tripping over the Truth follows the story of cancer’s proposed metabolic origin from the vaunted halls of the German scientific golden age to modern laboratories around the world. The reader is taken on a journey through time and science that results in an unlikely connecting of the dots with profound therapeutic implications.
Transporting us on a rich narrative of humanity’s struggle to understand the cellular events that conspire to form malignancy, Tripping over the Truth reads like a detective novel, full of twists and cover-ups, blind-alleys and striking moments of discovery by men and women with uncommon vision, grit, and fortitude. Ultimately, Christofferson arrives at a conclusion that challenges everything we thought we knew about the disease, suggesting the reason for the failed war against cancer stems from a flawed paradigm that categorizes cancer as an exclusively genetic disease.
For anyone affected by this terrifying disease and the physicians who struggle to treat it, this book provides a fresh and hopeful perspective. It explores the new and exciting non-toxic therapies born from the emerging metabolic theory of cancer. These therapies may one day prove to be a turning point in the struggle against our ancient enemy. We are shown how the metabolic theory redraws the battle map, directing researchers to approach cancer treatment from a different angle, framing it more like a gentle rehabilitation rather than all-out combat. In a sharp departure from the current “targeted” revolution occurring in cancer pharmaceuticals, the metabolic therapies highlighted have one striking feature that sets them apart—the potential to treat all types of cancer because they exploit the one weakness that is common to every cancer cell: dysfunctional metabolism.
With contributions from Thomas Seyfried, PhD, author of Cancer as a Metabolic Disease; Miriam Kalamian, EdM, MS, CNS, author of Keto for Cancer; and Beth Zupec Kania, consultant nutritionist of The Charlie Foundation.
Thoracic Oncology provides an up-to-date and concise review of the various thoracic neoplasms and offers a better understanding of the biology, natural history, diagnosis and treatment of these malignancies. This book will be of particular interest to clinicians interested in thoracic neoplasms, to better understand and treat them.
Traumatized and terrified of cancer? Perhaps you have been diagnosed yourself, or you have a friend or family member who is battling with the disease. You know you must face it—but you do not have to face it alone. Praying Through Cancer is a collection of stories by women who have faced cancer and, with triumphant spirits, found comfort and sometimes even joy in the midst of it.
For these women, cancer was a comma, not a period, in the sentences of their lives. Why? Because they put their faith in the Lord and He strengthened them beyond comprehension. You will laugh and you will cry, but best of all, you will know . . . you are not alone.
For more than two decades, readers faced with a diagnosis of breast cancer have relied on Dr. Susan Love's Breast Book to guide them through the frightening thicket of research and opinion to find the best options for their particular situations. This sixth edition explains advances in targeted treatments, hormonal therapies, safer chemotherapy, and immunologic approaches as well as new forms of surgery and radiation. There is extensive guidance for the many women now living for years with metastatic breast cancer. With Dr. Love's warm support, readers can sort the facts from the fads, ask the right questions, and recognize when a second opinion might be wise.
Ovarian carcinogenesis, invasion, and metastatic dissemination require a complex cascade of interrelated genetic, molecular, and biochemical events that regulate the neoplastic transition of normal ovarian surface epithelium.
This volume summarizes recent advances in ovarian cancer detection and treatment and provides an analysis of current research into aspects of malignant transformation, growth control, and metastasis. A more detailed understanding of these processes may ultimately translate into the development of novel approaches for the detection and control of ovarian cancer.
Cancer research has been notable for its periodic cycles of promise and hope, followed by defeat and disappointments. It is not that there is no solution, but that the problem has not been identified precisely. This book is our attempt to define the most crucial questions related to MDS that need to be addressed immediately through logic, analysis and rigorous experimentation. If the emerging problems appear daunting, then instead of being overwhelmed by them, we should follow the advice of the great 20th century thinker Antonio Gramsci, `pessimism of the intellect must be faced with the optimism of will'.
Because of the unique and comprehensive examination of liver tumors, this work is an excellent resource for surgical, transplant and medical oncologists, surgeons, gastroenterologists, and radiologists.
Non-Myeloablative Allogeneic Transplantation will provide both practitioners and academic clinicians with a better understanding of underlying concepts, current methodologies, and results obtained by the pioneering centers for this rapidly evolving field.
Essentials of Clinical Radiation Oncology has been designed to replicate a "house manual" created and used by residents in training and is a "one-stop" resource for practicing radiation oncologists, related practitioners, and radiation oncology residents entering the field.
Key Features:Offers digestible information as a learning guide for general practice Examines essential clinical questions which are answered with evidence-based data from important clinical studies Places clinical trials and data into historical context and points out relevance in current practice Provides quick reference tables on treatment options and patient selection, workup, and prognostic factors by disease site
Cancer is not randomly distributed in the United States. Its incidence varies by race, ethnicity, socioeconomic status, and other geographic and demographic factors. This volume, co-published with the American Cancer Society, is the first to examine the biological, racial, and socioeconomic factors that influence cancer incidence and survival. In addition, it presents 15 previously unpublished, evidence-based interventions to reduce and eliminate cancer disparities.
The book explains the nature, scope, and causes of cancer disparities across different populations and then presents unique programs proven to reduce such inequalities in the areas of cancer prevention, screening and early detection, treatment, and survivorship. They represent a variety of cancers, populations, and communities across the U.S. Descriptions of each intervention include tests of effectiveness and are written in sufficient detail for readers to replicate them within their own communities.Key Features:
Offers an in-depth look at the latest research behind cancer disparitiesWritten by highly respected and published cancer researchersIncludes 15 never-before published, evidence-based interventions that readers can replicateDiscusses breast, colorectal, cervical, and other pernicious cancersIncludes interventions for African-American, Hispanic, Native American, and other populations
Biostatistics is an essential component of basic and clinical cancer research. The text, authored by distinguished figures in the field, addresses clinical issues in statistical analysis. The spectrum of topics discussed ranges from fundamental methodology to clinical and translational applications.
Rancour has an honest, humane, funny, and poetic style. She sweeps you along with her compassion, her wit, and her unerring ability to see into the truth of the matter. This book is for anyone who has an interest in what goes on in the patient rooms, hallways, stairwells, and elevators of a cancer hospital. You wont be able to put it down.
This is a comprehensive summary of the current state of the art research and treatment.
This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents.
Series Editor comments:
"The biologic behavior of both normal and cancer cells is determined by critical signal transduction pathways. This text provides a comprehensive review of the field. Leading investigators discuss key molecules that may prove to be important diagnostic and/or therapeutic targets."
In this groundbreaking book, Gary Null debunks the commonly accepted belief that drugs and chemotherapy are the only cures for cancer and explores the alternative treatments that most mainstream doctors will never discuss with their patients. Dr. Null asserts that there are foods and supplements that boost the body’s immune system and can actually prevent and reverse cancer. Did you know that eating lemons and melons can help balance your body’s pH, which will help prevent and treat cancer? You knew that fiber is important for a healthy diet, but did you know that it lowers the risk of breast, colorectal, uterine, and prostate cancers? Have you heard of maitake mushrooms, which kill cancer cells by enhancing the activity of T-helper cells? In addition to diet, Dr. Null discusses important supplements and herbs and cutting-edge therapies you may never have heard of. With twenty-five cancer-fighting recipes and testimonials from individuals who have found health through Dr. Null’s methods, this book could save your life.
-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer.
Cowritten with DeVita’s daughter, the science writer Elizabeth DeVita-Raeburn, The Death of Cancer is also a personal tale about the false starts and major breakthroughs, the strong-willed oncologists who clashed with conservative administrators (and one another), and the courageous patients whose willingness to test cutting-edge research helped those oncologists find potential treatments. An emotionally compelling and informative read, The Death of Cancer is also a call to arms. DeVita believes that we’re well on our way to curing cancer but that there are things we need to change in order to get there. Mortality rates are declining, but America’s cancer patients are still being shortchanged—by timid doctors, by misguided national agendas, by compromised bureaucracies, and by a lack of access to information about the strengths and weaknesses of the nation’s cancer centers.
With historical depth and authenticity, DeVita reveals the true story of the fight against cancer. The Death of Cancer is an ambitious, vital book about a life-and-death subject that touches us all.
Both increased efforts by many investigators and advances in research methodologies have provided a wealth of information in the area of skeletal metastases. The Biology of Skeletal Metastases brings together experts to describe these many advances. This book provides background in basic bone biology and biology of metastasis for novice investigators and highlights many advances in this challenging field for the experienced investigator.
This book brings together up-to-date summaries by leading cancer researchers on the major principles of cancer cell biology: survival, apoptosis, adhesion, and cell cycle deregulation. It is directed at clinicians and scientists working in the areas of experimental and molecular therapeutics, molecular medicine, translational cancer research, and bio-medical sciences in general.
Lanzkowsky’s Manual of Pediatric Hematology and Oncology, Sixth Edition,is a comprehensive book on patient management, replete with algorithms and flow diagrams on diagnosis and management. Reflecting the considerable advances in the treatment and management of hematologic and oncologic diseases in children, the sixth edition of this successful clinical manual has been entirely updated to incorporate all current treatment protocols, new drugs, and management approaches. Its concise and easy-to-read format will enable readers to make accurate diagnoses and permit them to treat patients without having to reference larger medical textbooks.
Based on the new standards of genetic classification and prognostic information that have arisen in the past five years, the sixth edition includes two new chapters (Diagnostic, Molecular, and Genomic Methodologies for the Hematologist, Transfusion Medicine) and several new expanded chapters that were previously sections in consolidated chapters (Myelodysplasia, Myeloid Leukemias, Lymphoid Leukemias, Hemolytic Anemia, and Disorders of Coagulation).Presents a concise, systematic approach to all pediatric hematologic and oncologic disorders in one manualOffers an alternative to bigger references which only cover either oncologic or hematologic disorders in twice as many pagesPresents an easy-to-read format: multiple tables, charts, and flow-diagrams for diagnosis and management of pediatric hematologic and oncologic disordersIncludes 2 new chapters and several expanded chapters: Diagnostic, Molecular and Genomic Methodologies for the Hematologist, Transfusion Medicine, Myelodysplasia, Myeloid Leukemias, and Lymphoid Leukemias
In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.
Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.
Over the past half century, deaths from heart disease, stroke, and so many other killers have fallen dramatically. But cancer continues to kill with abandon. In 2013, despite a four-decade “war” against the disease that has cost hundreds of billions of dollars, more than 1.6 million Americans will be diagnosed with cancer and nearly six hundred thousand will die from it.
A decade ago, Clifton Leaf, a celebrated journalist and a cancer survivor himself, began to investigate why we had made such limited progress fighting this terrifying disease. The result is a gripping narrative that reveals why the public’s immense investment in research has been badly misspent, why scientists seldom collaborate and share their data, why new drugs are so expensive yet routinely fail, and why our best hope for progress—brilliant young scientists—are now abandoning the search for a cure. “Through flowing prose Leaf delivers, alongside facts and data, stories on personalities involved in research, the fascinating process of solving an unusual and highly deadly cancer in Africa, and the heartbreaking realities of cancer treatment in children today. Leaf’s extensively investigated treatise will resonate with researchers and patients frustrated by the bureaucratic woes he delineates. Public policy makers, grant reviewers, and pharmaceutical researchers alike must consider Leaf’s indictment and proposed solutions” (Publishers Weekly). The Truth in Small Doses is that rare tale that will both outrage readers and inspire conversation and change.
The contributions selected for the book cover a wide spectrum of theory and practice, being simultaneously of high theoretical level and deeply rooted in engineering problems. Thus, this volume touches on what is of key importance in electromagnetism.
As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeutic—making this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike.
KEY FEATURESConveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes
Oncology Board Review: Blueprint Study Guide and Q&A is a concise, outline-based study guide covering the topics that appear on the Medical Oncology Certification Exam. This second edition has been thoroughly revised to include new treatment regimens, clinical guidelines, and other updates impacting the field and reflected on the test.
The book includes all topics listed in the American Board of Internal Medicine (ABIM) blueprint as essential material for the Medical Oncology Certification Exam. The coverage spans all hematologic malignancies and solid tumors, beginning with the epidemiology, and followed by the etiology and risk factors of the disease, staging, signs and symptoms, diagnostic criteria, indications for treatment, prognostic factors, treatment recommendations, and special considerations. Later chapters review other major subspecialty areas found on the exam including cancer genetics and tumor biology, supportive and palliative care, bone marrow transplantation, and biostatistics. Each chapter includes key points summarized in digestible bullets for easy recall and self-assessment. And, now containing over 230 board style questions with answers and detailed rationales, Oncology Board Review, Second Edition is the go-to, quick review for any trainee preparing for initial certification and for oncologists preparing for recertification.New to this Edition:Includes over 230 board style questions and answers with rationalesNew chapter on Bone Marrow TransplantationThoroughly updated and revised chapters with all new treatment recommendations and FDA approvals for solid tumors and hematologic malignancies included.
In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of patients across the complex landscape of lymphoma subtypes. Researchers and practitioners alike will welcome this useful summary of the state of the art in this field.
Aids-Associated Viral Oncogenesis will specifically address viral-induced human cancers. Topics will cover the viral associated cancers observed in the AIDS population, specific treatment required in this special population, and molecular biology of the causative viral agents.
This is the first volume to provide a multidisciplinary approach to peritoneal carcinomatosis encompassing molecular mechanisms, histopathology, regional and systemic cytotoxic therapy, and surgical options. Peritoneal Carcinomatosis: A Multidisciplinary Approach will be of interest for medical, surgical and gynecological oncologists faced with the complexities of decision making in patients suffering from PC, as well as for basic and translational scientists active in the field of locoregional cancer spread. Numerous illustrations aid the reader throughout in the many facets of this disease.
· Molecular imaging advances help to localize early cancers more precisely.
· Current status of the immune responses in the draining lymph nodes against cancer is summarized.
· New paradigms of early cancer growth, proliferation, overcoming apoptosis are exploited in the development of anticancer treatment.
In this book, basic scientists and clinicians exchange ideas so that laboratory findings can be applied to clinical dilemmas, and clinical problems can be targeted for research in the laboratory.
An empathetic resource full of relatable patient stories, this book teaches patients and caregivers how to ask the right questions to get the best possible care--beginning at the moment of diagnosis. Drs. Jackson and Ryan explain how to work with a team of doctors and nurse practitioners to minimize symptoms and side effects while living as fully as possible in the face of cancer. They relay important information about understanding prognosis, and they translate what doctors mean when they describe tests, treatments, and medical procedures. Finally, they discuss hospice care and answer questions about continuing treatment and managing the final phase of life.
Based on new research and a groundbreaking program in which patients are treated with palliative care--along with the best cancer care--during the course of their illness, this honest and caring book provides the right advice to use at the right time throughout a journey with cancer. It allows a person with cancer to concentrate on living the best life possible, despite an uncertain future. Patients at every stage will find Living with Cancer a comprehensive, thoughtful, and accessible guide for navigating the illness and its treatment.
This book will bring current information on the presentation and management of patients with brain metastases, providing available data, giving guidelines that can be applied in day to day practice, updated information for neuro-surgeons, radiation oncologists, medical oncologists, and neuro-oncologists, as well as an overview for physicians in training.
Key challenges include integrating research and clinical care, sharing data, and establishing partnerships within and across sectors of patient diagnosis and treatment.
Addressing important clinical questions in cancer research will benefit from expanding computational biology.
The advent of genomic and proteomic technologies has ushered forth the era of genuine medicine. The promise of these advances is true "personalized medicine" where treatment strategies can be individually tailored and advance to initiating intervention before visible symptoms appear.